The intersection of technology and medicine is once again on display with Avenda Health’s Unfold AI. In a landmark study conducted by Stanford University School of Medicine, Unfold AI demonstrated unprecedented accuracy in detecting the extent of prostate cancer.
Utilizing machine learning, Unfold AI presents 3D cancer visualizations which offer precise information for physicians. This is a critical development, as it enables more personalized treatment options compared to the traditional whole-prostate approach, which has been known to have detrimental effects on sexual and urinary functions.
Unfold AI’s capabilities in determining cancer margins have been particularly notable, with the study highlighting an 80% rate of complete clinically significant prostate cancer encapsulation.
Shyam Natarajan, Ph.D., co-founder and CEO of Avenda Health, believes that this technology will provide a fresh perspective in a field that has seen little innovation in the past 40 years. With FDA clearance received in late 2022, Unfold AI is poised to make a significant impact on prostate cancer care.
Explore this groundbreaking technology at avendahealth.com.